ConforMIS Reports Third Quarter 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ConforMIS Reports Third Quarter 2015 Financial Results

BEDFORD, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS ), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today financial results for the third quarter ended September 30, 2015.

Q3 Summary:

  • ConforMIS resumed full production in October after resolving the issues associated with the voluntary recall that it announced on August 31, 2015
  • Total revenue of $13.9 million, up 16% year-over-year on a reported basis and up 20% year-over-year on a constant currency basis
  • Product revenue of $13.5 million, up 12% year-over-year on a reported basis and up 17% year-over-year on a constant currency basis
    • U.S. product revenue increased 19% year-over-year
    • Rest of World product revenue increased 11% year-over-year on a constant currency basis

"The third quarter of 2015 was challenging in view of the voluntary recall, but it turned into a productive quarter with an increase in product revenues of 17% year-over-year on a constant currency basis," said Philipp Lang, MD, MBA, Chief Executive Officer of ConforMIS, Inc. "We successfully navigated an unexpected production issue within the timeframes that we communicated and returned to full operations in October. While the voluntary recall in the third quarter affected our sales and gross margin as expected, we anticipate this will reverse course in the fourth quarter now that we have resumed full production. We also continued to expand our surgeon user base in the third quarter while the voluntary recall was ongoing. We believe this is a direct reflection of the clinical superiority of our products which also results in the strong loyalty shown by our existing surgeons. Additionally, the limited launch of our new knee product, the iTotal PS, is progressing favorably, and the Company anticipates a full commercial launch of that product at the American Academy of Orthopedic Surgeons in March of 2016, as originally planned."

  Three Months Ended September 30, Increase / Decrease
($, thousands) 2015 2014 $ Change % Change % Change
        (as reported) (constant currency)
United States $10,493 $8,804 $1,689 19% 19%
Rest of World 2,997 3,198 (201) -6% 11%
Product Revenue 13,490 12,002 1,488 12% 17%
Other Revenue 404 0 404 n/m n/m
Total Revenue $13,894 $12,002 $1,892 16% 20%

Third Quarter 2015 Financial Results

Total revenue increased $1.9 million to $13.9 million, or 16% year-over-year. Total revenue increased 20% year-over-year on a constant currency basis. Total revenue in the third quarter of 2015 includes royalty revenue of $0.4 million related to ongoing royalty payments.

Product revenue increased $1.5 million to $13.5 million, or 12% year-over-year on a reported basis and 17% on a constant currency basis. U.S. product revenue increased $1.7 million to $10.5 million, or 19% year-over-year, and Rest of World product revenue decreased $0.2 million to $3.0 million, or 6% year-over-year on a reported basis and increased 11% on a constant currency basis. Product revenue from sales of iTotal CR, iUni and iDuo increased $0.7 million to $12.7 million, or 6% year-over-year on a reported basis and 10% on a constant currency basis. Product revenue from sales of iTotal PS, which we launched on a limited basis in the United States in February 2015, was $0.8 million in the third quarter of 2015.

Gross profit decreased $1.1 million to $3.6 million, or 26% of revenue, compared to $4.7 million, or 39% of revenue, in the third quarter of 2014. The decrease in gross margin was primarily caused by the additional production costs and decrease in revenue due to the voluntary recall and, to a lesser extent, changes in foreign exchange rates compared to the prior year.

Total operating expenses increased $4.8 million to $19.8 million, or 32% year-over-year. The increase in expenses was driven primarily by higher sales and marketing and general and administrative expenses, which was offset by slightly lower research and development expense compared to the third quarter of 2014.

Net loss was $17.1 million, or $(0.45) per share, compared to a net loss of $10.4 million, or $(2.44) per share, for the same period last year.

2015 Financial Guidance

ConforMIS reaffirms the financial guidance provided on August 31, 2015.

For the full year 2015, the Company expects total revenue in a range of $64 million to $66 million, representing year-over-year growth of 33% to 37% on a reported basis and 39% to 43% on a constant currency basis. This revenue guidance includes an $8 million reduction in revenue from the voluntary recall. The Company's total revenue guidance also includes approximately $3 million of currency headwind in our revenue results.

The Company's 2015 revenue guidance assumes the following:

  • Product revenue in a range of $60 million to $62 million, representing year-over-year growth of 25% to 29% on a reported basis and 31% to 35% on a constant currency basis.
  • Royalty revenue of approximately $4 million, including the $3.9 million recognized in the first nine months of fiscal 2015 related to a patent litigation settlement and related license.

Constant Currency

The Company provides certain information regarding the Company's financial results or projected financial results on a "constant currency basis." This information estimates the impact of changes in foreign currency rates on the translation of the Company's current or projected future period financial results as compared to the applicable comparable period. This impact is derived by taking the adjusted current or projected local currency results and translating them into U.S. Dollars based upon the foreign currency exchange rates for the applicable comparable period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.

Conference Call

As previously announced, ConforMIS will conduct a conference call and webcast today at 4:30 PM Eastern Time. Management will discuss financial results and strategic matters. To participate in the conference call, please call 877-703-9876 (or 616-548-5612 for international) and use conference ID number 50086744 or listen to the webcast in the investor relations section of the company's website at ir.conformis.com. The online archive of the webcast will be available on the company's website for 30 days.

About ConforMIS, Inc.

ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. ConforMIS offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In recent clinical studies, ConforMIS iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. ConforMIS owns or exclusively in-licenses approximately 500 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints. 

For more information, visit www.conformis.com . To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/ .

Cautionary Statement Regarding Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for ConforMIS, including statements about ConforMIS's strategy, future operations, future financial position and results, market growth, total revenue and revenue mix by product and geography, gross margin, operating trends, the potential impact and advantages of using customized implants, the commercial launch of iTotal PS, and the impact of our voluntary recall and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates regarding the potential market opportunity for our current and future products, our expectations regarding our sales, expenses, gross margins and other results of operations, the impact of its manufacturing interruption on its financial results, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent ConforMIS's views as of the date hereof. ConforMIS anticipates that subsequent events and developments may cause ConforMIS's views to change. However, while ConforMIS may elect to update these forward-looking statements at some point in the future, ConforMIS specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ConforMIS's views as of any date subsequent to the date hereof. 

CONFORMIS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share data)
 
  Three Months Ended September 30, Nine Months Ended September 30,
  2015 2014 2015 2014
         
Revenue        
Product  $ 13,490  $ 12,002  $ 43,953  $ 33,975
Royalty  404  --   3,863  -- 
Total revenue  13,894  12,002  47,816  33,975
Cost of revenue  10,340  7,351  30,392  21,961
Gross profit  3,554  4,651  17,424  12,014
         
Operating expenses        
Sales and marketing  10,225  7,083  29,563  22,541
Research and development  3,885  3,969  12,218  11,163
General and administrative  5,656  3,927  16,790  11,775
Total operating expenses  19,766  14,979  58,571  45,479
Loss from operations  (16,212)  (10,328)  (41,147)  (33,465)
         
Other income and expenses        
Interest income  24  30  92  80
Interest expense  (911)  (89)  (1,380)  (178)
Other income (expense)  --  --  208  --
Total other expenses  (887)  (59)  (1,080)  (98)
Loss before income taxes  (17,099)  (10,387)  (42,227)  (33,563)
Income tax provision  8  9  29  29
         
Net loss  $ (17,107)  $ (10,396)  $ (42,256)  $ (33,592)
         
         
Net loss per share - basic and diluted  $ (0.45)  $ (2.44)  $ (2.69)  $ (7.95)
Weighted average common shares outstanding - basic and diluted  37,933,069  4,267,148  15,688,686  4,224,454
         
CONFORMIS, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(in thousands, except share and per share data)
     
  September 30, 2015 December 31, 2014
Assets  (unaudited)   
Current Assets    
Cash and cash equivalents  $ 139,202  $ 37,900
Accounts receivable, net  8,260  9,119
Inventories  10,664  7,691
Prepaid expenses and other current assets  2,124  1,158
Total current assets  160,250  55,868
Property and equipment, net  10,655  8,696
Other Assets    
Restricted cash  720  4,438
Intangible assets, net  1,057  1,243
Goodwill  753  753
Other long-term assets  283  280
Total assets  $ 173,718  $ 71,278
     
Liabilities and stockholder's equity    
Current liabilities    
Accounts payable  $ 5,849  $ 3,618
Accrued expenses  6,953  6,942
Deferred revenue  305  --
Current portion of long-term debt  289  272
Total current liabilities  13,396  10,832
Other long-term liabilities  240  271
Deferred revenue  4,701  --
Long-term debt  258  10,348
Total liabilities  18,595  21,451
Commitments and contingencies  --   --
Stockholders' equity    
Convertible preferred stock, $0.00001 par value:    
Authorized: 53,496,241 shares authorized, zero and 50,985,652 shares issued and outstanding September 30, 2015 and December 31, 2014, respectively; (aggregate liquidation value of $0 and $352,626 at September 30, 2015 and December 31, 2014, respectively)  --   --
Preferred stock, $0.00001 par value:    
Authorized: 5,000,000 and zero shares authorized at September 30, 2015 and December 31, 2014, respectively; no shares issued and outstanding as of September 30, 2015 and December 31, 2014  --   --
Common stock, $0.00001 par value:    
Authorized: 200,000,000 and 80,000,000 shares at September 30, 2015 and December 31, 2014, respectively; 40,709,155 and 4,286,164 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively  --   --
Additional paid-in capital  465,818  318,420
Accumulated deficit  (310,352)  (268,096)
Accumulated other comprehensive loss  (343)  (497)
Total stockholders' equity  155,123  49,827
Total liabilities and stockholders' equity  $ 173,718  $ 71,278

Investor contact Oksana Bradley (781) 374-5598

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 495

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 0

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 269

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 287

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 399

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 0

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

European Frozen Food Market Set for Major Growth, Companies Thrive

Updated Category News Views 277

European Frozen Food Market Set for Major Growth The frozen food market across Europe is poised for remarkable growth in the coming years, with an estimated increase of USD 62.5 billion from 2025 to 2029. With a projected compound annual growth rate (CAGR) of 7.6%, this sector is becoming increasingly attractive to investors and consumers alike. The desire for convenient...

Continue Reading
Mag Mile Capital's $10.25 Million Equity Venture in Chicago

Updated Category News Views 261

Mag Mile Capital Secures Significant Equity for Urban Transformation Mag Mile Capital, Inc. (OTCQB: MMCP) has achieved a significant milestone by securing $10.25 million in joint venture equity aimed at an innovative office-to-multifamily conversion project in Chicago. This project, situated at 111 W. Illinois, aims to repurpose a prominent office space in the vibrant...

Continue Reading
Nourishing Dogs and Communities: The Launch of Purposeful Pup Treats

Updated Category News Views 243

Purposeful Pup Treats Unveils New Launch for Furry Friends Purposeful Pup Treats, a brand passionate about the welfare of pets, has proudly launched a new range of all-natural, single-ingredient dog snacks. These treats are created with high-quality European ingredients and designed not just for the health of dogs, but also to uplift and strengthen communities. Embracing...

Continue Reading
Collaboration of Linux Foundation and ATIS to Transform Telecom

Updated Category News Views 151

Strategic Partnership for Innovative Network Solutions The Linux Foundation and the Alliance for Telecommunications Industry Solutions (ATIS) have joined forces to create a transformative impact on next-generation network architectures. This collaboration paves the way for advancements in open source and open RAN technologies, which are becoming increasingly important in...

Continue Reading
Vallourec Expands Operations with Significant Contracts

Updated Category News Views 245

Vallourec's Strategic Contracts in Iraq Vallourec, a global leader in premium seamless tubular solutions, has recently cemented two significant contracts for the supply of Oil Country Tubular Goods (OCTG). These contracts, established with major players CNOOC and PetroChina, reflect Vallourec's strength and expertise in supporting drilling operations in challenging...

Continue Reading